Early/midstage study begins for OncoMed stem cell drug

09/19/2013 | RTT News

OncoMed Pharmaceuticals has begun a Phase Ib/II study to assess the efficacy of its anti-cancer stem cell candidate OMP-21M18, or demcizumab, with paclitaxel against platinum-resistant ovarian cancer, primary peritoneal cancer and fallopian tube cancer. The drug is also in early stage trials against pancreatic cancer and nonsmall-cell lung cancer.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Santa Clara, CA
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA